Form 4: Replimune CFO Receives Significant Equity Grants

Replimune Group's Chief Financial Officer Emily Luisa Hill was granted 50,000 restricted stock units and 75,000 stock options as part of a long-term incentive package.

Summary

• Emily Luisa Hill, the Chief Financial Officer of Replimune Group, Inc., was granted 50,000 Restricted Stock Units (RSUs) on April 1, 2026.
• The CFO also received 75,000 employee stock options with an exercise price of $7.61 per share.
• The RSUs vest over a four-year period, with 25% vesting on May 15, 2027, and the remainder in three annual installments through 2030.
• The stock options vest over four years, with 25% vesting on April 1, 2027, followed by 36 monthly installments.
• Following these transactions, Hill's direct ownership in the company increased to 244,368 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive due to the clear long-term incentive alignment for the CFO, though the administrative delay in filing is a minor negative factor.

Positives

• Strong alignment of executive interests with shareholders through a four-year vesting schedule extending to 2030.
• The CFO maintains a significant equity stake in the company with over 244,000 shares owned directly.
• The use of stock options with a $7.61 strike price provides a clear incentive for management to drive share price appreciation.

Negatives

• The filing was submitted late due to an inadvertent administrative error, which may indicate minor lapses in internal reporting controls.
• The grants represent a potential future dilution of approximately 125,000 shares for existing shareholders.

Risks

• Administrative errors in SEC filings can occasionally lead to increased regulatory oversight or scrutiny of internal controls.
• The ultimate value of the compensation is entirely dependent on the company's stock performance and the CFO's continued employment through 2030.

Future Outlook

The long-term vesting structure of these grants suggests that the company is focused on executive retention through at least 2030, aligning management's financial rewards with the long-term growth of the company.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, heavy reliance on equity-based compensation is standard practice to preserve cash while ensuring key executives remain committed during lengthy clinical development and regulatory approval cycles.

Comparison to Industry Standards

• The four-year vesting period is consistent with industry standards for mid-cap biotech companies like Moderna or Alnylam.
• A mix of RSUs and stock options is a common balanced approach used by companies in the Nasdaq Biotechnology Index to reward both retention and performance.

Corporate Governance

Related Party Transactions

• The grant of equity securities to the CFO is a related party transaction between the issuer and an executive officer.

Stakeholder Impact

• Shareholders: Face a minor potential dilution of approximately 125,000 shares over the next four years.
• Management: The CFO receives a significant financial incentive tied to the company's long-term stock performance.

Next Steps

• Initial vesting of stock options on April 1, 2027.
• Initial vesting of restricted stock units on May 15, 2027.

Key Dates

Recommendation

The filing reflects routine executive compensation and retention strategies. While the CFO's increased stake is a positive sign of internal confidence, the transaction itself is not a catalyst for a significant change in investment thesis.

Keywords

Replimune Group, REPL, CFO Compensation, Restricted Stock Units, Stock Options, Insider Ownership, Equity Grant, Biotechnology